Patricia Matlock
Family · Tomball, TXNPI 1336264894
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 462 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 462 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Lilly USA, LLC$692
- Novo Nordisk$644
- AstraZeneca$592
- Boehringer Ingelheim$536
- Abbott$459
- plus $4K from 46 others
What the payments were for
- Food & beverage$7,747100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,747 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 76 | $89,750 |
| MounjaroTirzepatide | 58 | $60,010 |
| EliquisApixaban | 59 | $56,549 |
| OzempicSemaglutide | 38 | $52,703 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $46,954 |
| VascepaIcosapent Ethyl | 33 | $26,369 |
| XareltoRivaroxaban | 11 | $17,761 |
| JanuviaSitagliptin Phosphate | 16 | $13,482 |
| EntrestoSacubitril/Valsartan | 16 | $10,795 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $10,543 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $6,645 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 18 | $5,775 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,651 |
| Levothyroxine Sodium | 407 | $4,761 |
| Rosuvastatin Calcium | 377 | $4,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $536 | $89,75076 claims |
| PfizerEliquis, Abrysvo | $315 | $62,32477 claims |
| Lilly USA, LLCMounjaro | $692 | $60,01058 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $1,045 | $57,04366 claims |
| Novo NordiskOzempic | $644 | $52,70338 claims |
| Johnson & JohnsonXarelto | $20 | $17,76111 claims |
| MerckJanuvia | $104 | $13,48216 claims |
| AstraZenecaBreztri Aerosphere | $592 | $10,54311 claims |
| AbbVieSynthroid | $433 | $1,45328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Tomball
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.